News

Xilio Therapeutics Unveils Promising Data for Tumor-Activated Therapies

Xilio Therapeutics Unveils Promising Data for Tumor-Activated Therapies

Xilio Therapeutics Highlights Advancements in Cancer Treatment Trials

Xilio Therapeutics, Inc. (Nasdaq: XLO), a pioneering clinical-stage biotechnology company, is making significant strides in the development of tumor-activated immuno-oncology therapies aimed at improving outcomes for cancer patients. Recently, the company announced exciting plans to share initial data from its ongoing Phase 2 trial involving vilastobart (XTX101), a tumor-activated, high-affinity binding anti-CTLA-4 antibody. This presentation is set to take place at the prestigious ASCO Gastrointestinal (ASCO GI) Cancers Symposium.

Initial Findings from Vilastobart Trial

Scheduled for the ASCO GI event, Xilio will reveal findings related to the combination of vilastobart and atezolizumab (Tecentriq) specifically for patients suffering from metastatic microsatellite stable colorectal cancer (MSS CRC). The preliminary data collected from the earlier Phase 1C dosage escalation trials has already shown promise, indicating encouraging responses in patients with cold tumors, including MSS colorectal cancer.

Quote from Xilio's Chief Medical Officer

Dr. Katarina Luptakova, the Chief Medical Officer at Xilio, expressed her optimism regarding the trial results. "The initial responses we've observed in patients undergoing treatment with vilastobart and atezolizumab during our Phase 1 trials are quite promising. We can't wait to present the comprehensive data at ASCO GI,” she noted. Moreover, the excitement surrounding the preliminary Phase 1 data for XTX301, an investigational tumor-activated IL-12, adds to the anticipation of future advancements in cancer therapy.

Details of the ASCO GI Presentation

Xilio's ASCO GI presentation will outline the combination therapy's initial data from the ongoing Phase 2 trial. The specifics of the presentation are:

  • Title: Phase 1/2 study of XTX101 in combination with atezolizumab for advanced solid tumors and MSS CRC
  • Abstract Number: 206
  • Presentation Date: January 25, 2025
  • Poster Session C: Cancers of the Colon, Rectum, and Anus
  • Time: 7:00 AM-7:55 AM PST
  • Location: Moscone West, San Francisco, CA

Insights from Preliminary Phase 1 Data for XTX301

The company has observed significant progress in the clinical trial for XTX301, a novel tumor-activated IL-12. Preliminary findings show that XTX301 has the potential to enhance anti-tumor immunity without dose-limiting toxicities, a common concern in cancer therapies. Particularly noteworthy is the clinical profile of XTX301, which has demonstrated sustained interferon gamma signaling without the unpleasant effects typically associated with similar agents.

Patient Treatment Details

As of a recent data assessment, 34 patients with advanced solid tumors received XTX301 dosages ranging from 5 µg/kg to 60 µg/kg, administered every three weeks or six weeks. Most participants had undergone three or more prior lines of anti-cancer therapy, indicating the need for innovative solutions in heavily pre-treated patients.

Financial Developments with Gilead

Xilio also confirmed a significant financial boost through a recent private placement with Gilead Sciences, incurring an aggregate of approximately $8.2 million. This transaction is part of a series of financial engagements initiated in 2024, securing nearly $25 million. These funds are expected to sustain operational expenses and capital requirements well into late 2025, a reassuring signal for continued research and development efforts.

Understanding Vilastobart and XTX301

Vilastobart represents an innovative approach as a tumor-activated, Fc-enhanced monoclonal antibody. It acts by blocking CTLA-4 and selectively disrupting regulatory T cell functions within the tumor microenvironment. The collaborative efforts with Roche to evaluate vilastobart alongside atezolizumab have the potential to revolutionize treatments for conditions resistant to existing therapies.

Exploring XTX301

XTX301 is designed to invigorate the immune response and reprogram the tumor microenvironment of cancer patients with poorly immunogenic tumors. An exclusive license agreement with Gilead has propelled this program forward, ensuring that it remains at the forefront of immuno-oncology research.

About Xilio Therapeutics

As an innovative company committed to enhancing cancer treatments, Xilio Therapeutics is focused on developing tumor-activated immuno-oncology therapies that aim to minimize systemic side effects while maximizing therapeutic efficacy. Their unique platform continues to advance the discovery of new therapeutic avenues, consisting of cytokines, antibodies, bispecifics, and immune cell engagers dedicated to improving patient outcomes.

Frequently Asked Questions

What is XTX101?

XTX101, also known as vilastobart, is a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody designed to block CTLA-4 in the tumor microenvironment.

What was recently announced by Xilio Therapeutics?

Xilio announced initial data from their Phase 2 trial of XTX101 and preliminary data on XTX301, demonstrating their potential in treating solid tumors.

When will the ASCO GI presentation occur?

The presentation on XTX101 is scheduled for January 25, 2025, at the ASCO Gastrointestinal Symposium.

How does XTX301 work?

XTX301 is designed to stimulate anti-tumor immunity and transform the tumor microenvironment to enhance the treatment of cold tumors.

What future prospects exist for Xilio Therapeutics?

Xilio aims to continue developing its tumor-activated therapies to provide improved treatment options for cancer patients and to leverage partnerships with organizations like Gilead and Roche.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Ontario Airport Braces for Holiday Travel Surge

Updated Category News Views 92

Gearing Up for a Thanksgiving Travel Boom Think Thanksgiving brings only turkey to the table? Down in Ontario, California, it's all about jet fuel and passenger counts. The Ontario International Airport (ONT) is where the skies are buzzing, forecasting over 227,000 passengers trying to soak up the holiday vibes by air. Compare that to the numbers when the local folks...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 71

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
First Time Homebuyer Tips for Southern Maryland Success

Updated Category News Views 54

Shaking Up First-Time Homebuyer Assumptions Ever hear that age-old nonsense about needing a fat stack of cash as a down payment before you can snag your first home? Yeah, turns out that's about as outdated as a rotary phone. Robin Cavallaro from RE/MAX Realty Group in Annapolis is setting the record straight for first-time buyers in Southern Maryland. Down Payment Myths...

Continue Reading
HLTH USA 2026 Spotlights AI and Health Innovation

Updated Category News Views 77

The Pulse of Innovation at HLTH USA 2026 Diving headfirst into the heart of healthcare innovation, HLTH USA 2026 kicked off with gusto in Las Vegas. Discussions are swirling around AI advancements and the next generation of payer-provider collaboration. Who knew healthcare could be this thrilling? The event is already shaping up to be a powerhouse of change, buzzing with...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 60

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 89

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading
Rock Tech Uncovers Major Lithium Discovery at Victory

Updated Category News Views 84

Rock Tech's Game-Changer at Victory Folks, we've got a shake-up in the lithium landscape over in Ontario, courtesy of Rock Tech Lithium Inc. They just unearthed something quite promising at their Victory Project: a spanking new spodumene-bearing pegmatite discovery. Now I know, if you're like me, you're thinking, 'What's the angle here?' Well, this isn't just another hole...

Continue Reading
Pine Tree Bets Big on Tulsa Hills Shopping Center

Updated Category News Views 152

Pine Tree's Latest Move in Retail Real Estate Ya ever watch a company make a move so aligned with its playbook that it feels like a script straight outta the boardroom? That's Pine Tree with its recent snag of Tulsa Hills Shopping Center for a cool $108 million. This ain't just any retail spot; it's a bustling hub nestled within the posh outskirts of Jenks, Oklahoma....

Continue Reading
Kansai Powers Up US Grid with Bold Investment Move

Updated Category News Views 99

Betting Big on Battery Storage Let's unpack this big move by Kansai Electric. Anytime a major player like Kansai steps out of its home turf, folks better pay attention. Looks like Kansai's gotten cozy with Elevate and ArcLight, nabbing a minority stake in Prospect Power. This ain't your average widget factory—it's a beefy 150MW/600MWh battery energy storage facility in...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 109

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading

Top 5 Most Recently Viewed Articles

Algeness® VL Filler Receives Marketing Approval in China

Updated Category News Views 273

Exciting Developments for Advanced Aesthetic Technologies Advanced Aesthetic Technologies, Inc. (AAT) recently celebrated a significant milestone with the approval of their Algeness® VL agarose facial injection filler for marketing in China. This landmark achievement opens up new avenues for AAT in expanding their product offerings in the Asian market and showcases their...

Continue Reading
Criminal Charges Anticipated in Trump Campaign Hacking Case

Updated Category News Views 154

Criminal Charges Expected in Trump Campaign Hacking Case U.S. authorities are preparing to file criminal charges regarding an incident in which the Trump campaign claimed its internal communications were hacked, allegedly by the Iranian government. This concerning situation has drawn the attention of both the public and officials, raising serious issues surrounding...

Continue Reading
Semler Scientific Faces Class Action Lawsuit: What Investors Need to Know

Updated Category News Views 187

Semler Scientific and the Class Action Lawsuit Overview In recent news, a class action lawsuit has taken center stage involving Semler Scientific, Inc. (SMLR). Investors who have experienced losses related to their investments in Semler are advised to take note of this development, which may directly impact their financial outcomes. Understanding the Lawsuit This class...

Continue Reading
FTC Solar Engages Investors at Key Industry Conferences

Updated Category News Views 159

FTC Solar Engages Investors at Key Industry Conferences FTC Solar, Inc. (Nasdaq: FTCI), an innovative leader in solar tracker systems and engineering services, is set to make significant strides in connecting with investors at three prominent conferences. These events provide a platform for the management team, including CEO Yann Brandt, to engage in discussions that...

Continue Reading
Anixa Biosciences Set to Share Innovations in Cancer Therapy

Updated Category News Views 88

Anixa Biosciences Set to Conduct a Notable Presentation Anixa Biosciences, Inc. (NASDAQ: ANIX), a leading biotechnology firm dedicated to the treatment and prevention of cancer, has taken a significant step forward by announcing its participation in a prestigious investment conference. This event, the H.C. Wainwright 27th Annual Global Investment Conference, promises to...

Continue Reading